immune system
• tamoxifen-treated mice challenged with sheep red blood cell (sRBC) immunization show altered ratios of naive and effector/central memory CD4+ and CD8+ T cells in the spleen
|
• tamoxifen-treated mice challenged with sheep red blood cell (sRBC) immunization show increased CD4+ T cell numbers in the spleen
|
• tamoxifen-treated mice challenged with sRBC or OVA/Alum immunization show an increase in T follicular cells
|
• tamoxifen-treated mice challenged with sRBC or OVA/Alum immunization show expanded germinal center (increased GL7/B220+ B cells)
• while GCs are expanded, they show normal gross morphology with no increase in follicle size but more GL7+ area per follicle
• however, mice do not show increased GC reactions after a booster immunization of sRBCs
|
• tamoxifen-treated mice challenged with sheep red blood cell (sRBC) immunization show altered adaptive response after immunization, with more T follicular (Tfol) cells but no change in the ratio of T follicular helper (Tfh) to T follicular regulatory (Tfr) cells, expanded germinal centers (GCs; increased GL7/B220+ B cells) and higher titers of serum anti-sRBC IgG
• tamoxifen-treated mice challenged with sRBC immunization show increased numbers of CD4+ T cells and altered ratios of nave and effector/central memory CD4+ and CD8+ T cells in the spleen
• tamoxifen-treated mice challenged with OVA/Alum show increased Tfol cells and expanded GCs
• tamoxifen-treated mice still show increased Tfol cells and CD4+ T cells, altered ratios of CD4+/CD8+ subtypes, and increased IFN-gamma expression in CD4+/CD8+ T cells after a booster immunization of sRBCs
• however, splenic Treg level is not altered in tamoxifen-treated mice challenged with sRBC
• however, mice do not show increased GC reactions after a booster immunization of sRBCs, with titer or serum anti-sRBC IgG no different from controls and no higher than those seen after a single immunization
• administration of Anakinra (IL-1RA) reverses the increased responses
|
• tamoxifen-treated mice challenged with sRBC immunization show higher titers of serum anti-sRBC IgG
• however, mice show no differences in titer of serum anti-sRBC IgG after a booster immunization of sRBCs from controls and no higher levels than those seen after a single immunization
|
hematopoietic system
• tamoxifen-treated mice challenged with sheep red blood cell (sRBC) immunization show altered ratios of naive and effector/central memory CD4+ and CD8+ T cells in the spleen
|
• tamoxifen-treated mice challenged with sheep red blood cell (sRBC) immunization show increased CD4+ T cell numbers in the spleen
|
• tamoxifen-treated mice challenged with sRBC or OVA/Alum immunization show an increase in T follicular cells
|
• tamoxifen-treated mice challenged with sRBC or OVA/Alum immunization show expanded germinal center (increased GL7/B220+ B cells)
• while GCs are expanded, they show normal gross morphology with no increase in follicle size but more GL7+ area per follicle
• however, mice do not show increased GC reactions after a booster immunization of sRBCs
|
• tamoxifen-treated mice challenged with sRBC immunization show higher titers of serum anti-sRBC IgG
• however, mice show no differences in titer of serum anti-sRBC IgG after a booster immunization of sRBCs from controls and no higher levels than those seen after a single immunization
|